Recon: Sanofi to acquire Blueprint in $9B deal; FDA approves Moderna’s next-gen COVID vaccine for older adults

• The shrewd startup founder who led DOGE’s cost-cutting at HHS (STAT)
• Phase 3 or bust: Why Lilly won't run mid-stage cancer trials (Endpoints)
• Sanofi to buy Blueprint Medicines in deal worth more than $9 billion (STAT)
• mRNA, once lauded as a scientific marvel, is now a government target (STAT)
• US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older (Reuters)
• Musk's Neuralink raises $650 million in latest funding as clinical trials begin (Reuters)

• Sanofi’s vaccine tech transfer in Vietnam; Almac’s £1B+ revenue milestone (Endpoints)
• Korean startup Curogen seeks global expansion, new funding to back autoimmune drugs (Endpoints)
• Siemens Healthineers Widens FY25 EPS Range By €0.15 To Absorb Up To €300M In Tariff Costs (MedTech Insight)
• Japan Price Cuts For Epkinly and Lunsumio Following CEA (Pink Sheet)

• Bristol Myers to partner with BioNTech on experimental cancer drug (STAT)
• Enhertu, used as first option, stalled tumors for more than a year in women with breast cancer, study finds (STAT)
• Kymera reports early-stage success for drug meant to rival Sanofi and Regeneron’s Dupixent (STAT)
• Vera Therapeutics reports positive results from trial of kidney disease drug (STAT)
• Atai Life Sciences plans to merge with psychedelic startup Beckley Psytech (STAT)
• AstraZeneca’s CEO balances cancer-fighting opportunities with political uncertainty (STAT)
• Defying death two years after brain cancer diagnosis: studies build hope in CAR-T (STAT)
• In race with Merus, Bicara makes the case for two-year survival data (Endpoints)
• AstraZeneca details its oral SERD 'switching' regimen as feasibility questions remain (Endpoints)
• Regeneron's weight-loss drug combo helps preserve muscle in study (Reuters)
• Amgen drug cuts small cell lung cancer death risk by 40% (Reuters)
• Gilead's CAR-T cell therapy shows promise in deadly brain cancer (Reuters)

• FDA plans to begin rolling out AI tool agency-wide on Tuesday (STAT)
• Bivacor wins FDA breakthrough nod for titanium total artificial heart (MedTech Dive)
• Beta Bionics CEO, CFO on how to take a company public (MedTech Dive)
• Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System (MedTech Insight)
• SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US (MedTech Insight)

• Candy makers worry timeline to remove artificial dyes too ‘aggressive’ (Food Dive)
• JBS USA to build $135M sausage plant in Iowa (Food Dive)
• Nestlé, Mondelēz leave the US Plastics Pact (Food Dive)
• AFIA Decries ‘Oversimplification’ of Claims in MAHA Report (Food Safety)

• Amid measles outbreak, Texas is poised to make vaccine exemptions for kids easier (STAT)
• FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures (MedTech Insight)
• Drug, Biologic Policy Staff Return To US FDA, As RIF Process Hangs In Legal Limbo (Pink Sheet)\
• US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE (Pink Sheet)